Physician profile
Steven Mark Saba
NPI 1457962524
$1,629.98
in general payments reported to CMS, 2019-2025
15 companies · $459 in 2025
The $459 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $153 · 2023: $423 · 2024: $489 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,371.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $319.32 | 2023-2025 | Xen Glaucoma Treatment System, Lumigan, Vuity |
| Coopervision INC. | $310.53 | 2023-2025 | Clariti Contact Lens, Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $185.16 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $141.33 | 2022-2025 | Rocklatan, Eysuvis |
| Novartis Pharmaceuticals Corporation | $114.01 | 2022 | |
| Glaukos Corporation | $105.58 | 2021 | |
| Rxsight INC | $92.18 | 2024-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Dompe US, INC. | $81.93 | 2024-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $69.95 | 2023-2025 | Acuvue |
| Apellis Pharmaceuticals, INC. | $66.36 | 2025 | Syfovre |
| Mallinckrodt Hospital Products INC. | $43.54 | 2023 | Acthar |
| Sun Pharmaceutical Industries INC. | $35.37 | 2024-2025 | |
| Thea Pharma INC. | $23.38 | 2025 | Iyuzeh |
| Bausch & Lomb Americas INC. | $20.88 | 2022 | |
| Biotissue Holdings INC. | $20.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Saba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.